Bristol Myers to discontinue trial for colorectal cancer treatment

[December 16, 2023]  (Reuters) - Bristol Myers Squibb said on Friday it would discontinue its late-stage trial testing a treatment for a type of colon cancer.

The company said an independent data monitoring committee's analysis showed the trial was unlikely to meet its primary endpoints upon completion.

The trial was evaluating a combination therapy in patients who received previous treatment for a kind of colorectal cancer.

The company said the therapy did not have any safety concerns and it will be investigated as a treatment for other types of tumors.

(Reporting by Christy Santhosh; Editing by Maju Samuel and Shinjini Ganguli)

Test tubes are seen in front of a displayed Bristol Myers Squibb logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

[© 2023 Thomson Reuters. All rights reserved.]This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.